Biohaven migraine drug sales again top Wall Street forecasts

Sales of Biohaven Pharmaceutical's migraine medicine Nurtec ODT shot past Wall Street forecasts once again in the third quarter, as demand rose for the only treatment approved by the Food and Drug Administration for both treating and preventing the debilitating headaches.